Kisspeptin-10

Amidated KISS1(45–54) decapeptide · KISS1R/GPR54 research agonist

≥ 99.0% · target, verify batch COACAS 374675-21-5RUO

Research statusInvestigational; no FDA-approved indication reference context · supplied material is RUO

Supplied formDecapeptide (linear)

Lead time10–18 days

Kisspeptin-10 — Lyophilized material; confirm released-lot appearance on the COA

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research value includes KISS1R/GPR54 signaling, GnRH/LH pulse physiology, reproductive-axis pharmacodynamics, isoform PK comparisons, receptor desensitization, peptide aggregation and formulation research
IVF live-birth, OHSS, HSDD and intranasal outcomes from Kisspeptin-54 must not be marketed as KP-10 benefits.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 374675-21-5
Formula: C₆₃H₈₃N₁₇O₁₄
Molecular weight: 1302.4 g/mol
Appearance: Lyophilized material; confirm released-lot appearance on the COA
Purity: ≥ 99.0% · target, verify batch COA
Storage: Use the released lot's COA and formulation-specific stability instructions. Control light, temperature, moisture, adsorption, aggregation, matrix, concentration, container and freeze-thaw exposure. Rat decomposition data and vendor guidance do not establish a universal reconstituted shelf life.
MOQ: On request
Lead time: 10–18 days

PubChem CID 25240297

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Kisspeptin-10

Kisspeptin-10 is the amidated 10-residue C-terminal active sequence of KISS1-derived kisspeptins and an agonist of KISS1R/GPR54. Genetics establishes the pathway's central role in puberty and reproductive endocrine signaling, and a small intravenous study in healthy men demonstrated KP-10-induced LH responses. Most widely cited IVF, hypothalamic-amenorrhea, HSDD and intranasal studies used Kisspeptin-54, not KP-10. FDA found insufficient evidence to conclude that KP-10 is effective for secondary hypogonadism in men.

Appropriate research contexts include reproductive neuroendocrine signaling, controlled human PD studies, KISS1R pharmacology, puberty/hypogonadism genetics, isoform comparison, desensitization and formulation/aggregation studies
Evidence from Kisspeptin-54 IVF, amenorrhea, psychosexual and intranasal programs is class context, not direct KP-10 efficacy.

Mechanism context

The question the literature is testing

KP-10 activates KISS1R/GPR54 within the reproductive neuroendocrine axis and can stimulate GnRH-dependent gonadotropin secretion. Response magnitude and desensitization depend on isoform, exposure pattern, dose, sex and physiological state. A short circulating half-life does not justify a weekly schedule, and pathway biology does not validate TRT, fertility-preservation or post-cycle protocols.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaHormonal research

Routes reported in sources

SubcutaneousIntravenousIntramuscularIntranasal

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Research-use-only material; not for human or veterinary administration
FDA identified inadequate characterization, insufficient effectiveness evidence for secondary hypogonadism, limited route-specific safety information and potential immunogenicity amplified by aggregation or peptide-related impurities
FDA proposed not including Kisspeptin-10 on the 503A Bulks List, and PCAC voted 0–11 against inclusion because convincing safety and efficacy data were lacking; the advisory vote is non-binding
This lot is not an approved fertility, HSDD or hormone therapy product.

Interactions reported in the literature

No validated retail interaction or compatibility table exists
Do not infer safe synergy with GnRH, hCG, testosterone, estrogen, fertility protocols or anabolic-steroid post-cycle therapy
Experimental co-exposure requires endocrine monitoring, prespecified controls and institutional review.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Kisspeptin-10 factory batch COAs

Kisspeptin-10 5 mg Factory batch COA protected preview

Kisspeptin-105 mg · WHJLP-KS5-260324-D

Kisspeptin-10 10 mg Factory batch COA protected preview

Kisspeptin-1010 mg · WHJLP-KS10-260324-D

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require complete sequence and C-terminal amidation, intact mass, peptide content, related-peptide and aggregate profiles, counterion, water and residual solvents, plus light- and formulation-specific stability
Add validated endotoxin, bioburden or sterility controls only when the research model requires them
White powder or a clear solution alone does not establish identity or suitability.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

KP10-05MG5 mg10 vials

KP10-10MG10 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Use the released lot's COA and formulation-specific stability instructions. Control light, temperature, moisture, adsorption, aggregation, matrix, concentration, container and freeze-thaw exposure. Rat decomposition data and vendor guidance do not establish a universal reconstituted shelf life.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Direct KP-10 evidence: George et al. 2011 (PMID 21632807), small healthy-male intravenous PD study; KP-10/KP-54 persistence comparison (PMID 28464043); and rat analytical/stability work (PMID 23524040). Pathway genetics: Seminara et al. and de Roux et al. 2003. Kisspeptin-54 studies in amenorrhea, IVF, HSDD and intranasal delivery are retained only with explicit isoform separation. FDA compounding-review materials, the proposal not to include Kisspeptin-10 on the 503A Bulks List and the non-binding 0–11 PCAC vote control current risk and effectiveness wording.

01
The GPR54 gene as a regulator of puberty
New England Journal of Medicine · 2003 · peer-reviewed original research (landmark human/mouse genetics)
Open source
02
Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54
Proceedings of the National Academy of Sciences U.S.A. · 2003 · peer-reviewed original research (landmark human genetics)
Open source
03
Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
The Journal of Clinical Endocrinology & Metabolism · 2011 · peer-reviewed original research (human pharmacodynamic study)
Open source
04
Increasing LH Pulsatility in Women With Hypothalamic Amenorrhoea Using Intravenous Infusion of Kisspeptin-54
The Journal of Clinical Endocrinology & Metabolism · 2014 · peer-reviewed original research (human clinical pharmacology, placebo-controlled)
Open source
05
Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization
Journal of Clinical Investigation · 2014 · peer-reviewed original research (human clinical trial)
Open source
06
Kisspeptin modulates sexual and emotional brain processing in humans
Journal of Clinical Investigation · 2017 · peer-reviewed original research (randomized, double-blind, human fMRI study)
Open source
07
Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
JAMA Network Open · 2023 · peer-reviewed original research (randomized, double-blind, placebo-controlled crossover clinical trial)
Open source
08
Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
JAMA Network Open · 2022 · peer-reviewed original research (randomized, double-masked, placebo-controlled crossover clinical trial)
Open source

Product FAQ

Questions buyers ask about Kisspeptin-10

How does Kisspeptin-10 differ from Kisspeptin-54 and other KISS1 fragments?+

Kisspeptin-54, -14, -13 and -10 share the amidated C-terminal RF-amide sequence that activates KISS1R/GPR54, but they are different analytes with different length, stability and pharmacokinetic behavior. KP-10 is YNWNSFGLRF-NH₂; a KP-54 IVF, amenorrhea, HSDD or intranasal result cannot be relabeled as KP-10 evidence. An order and study report must identify the exact isoform, termini, salt, formulation and exposure protocol.

Which identity and quality attributes are critical for a Kisspeptin-10 lot?+

Specify H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂, C-terminal amidation, stereochemistry and counterion. Require high-resolution intact mass, sequence-confirming identity, quantitative peptide content, related-peptide and aggregate profiles, water and residual solvents, plus light- and formulation-specific stability. A white powder, clear solution, CAS or HPLC area purity alone cannot distinguish KP-10 from another kisspeptin fragment or establish usable concentration.

Kisspeptin-10

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Kisspeptin-10

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Kisspeptin-10 factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

The GPR54 gene as a regulator of puberty

Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54

Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men

Increasing LH Pulsatility in Women With Hypothalamic Amenorrhoea Using Intravenous Infusion of Kisspeptin-54

Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization

Kisspeptin modulates sexual and emotional brain processing in humans

Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial

Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial

Questions buyers ask about Kisspeptin-10

Compare adjacent molecules and documentation needs.

Oxytocin Acetate

ACTH (1-39)

HCG

Menotropins (HMG)